HCW Biologics (HCWB) Gross Margin (2022 - 2026)

HCW Biologics (HCWB) has reported Gross Margin for 5 consecutive years, with 69.25% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin fell 8925.0% year-over-year to 69.25%; the trailing twelve-month figure through Jun 2026 stood at 45.5% (down 6550.0% YoY), and the FY2025 full-year result was 20.0%, down 1738.0% from the prior year.
• Gross Margin slipped to 69.25% in Q2 2026 per HCWB's latest filing, from 20.0% in the prior quarter.
• Across five years, Gross Margin topped out at 57.4% in Q1 2022 and bottomed at 69.25% in Q2 2026.
• Historically, Gross Margin has averaged 21.02% across 5 years, with a median of 20.0% in 2022.
• The sharpest annual moves came in 2024 and 2026: Gross Margin soared 2464 bps in 2024, then sank 8925 bps in 2026.
• Over 5 years, Gross Margin stood at 20.0% in 2022, then slipped by 5 bps to 19.08% in 2023, then grew by 5 bps to 20.0% in 2024, then retreated by 0 bps to 20.0% in 2025, then plunged by 446 bps to 69.25% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 69.25%, 20.0%, and 20.0% for Q2 2026, Q4 2025, and Q3 2025 respectively.